Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 15/20 | 0.49 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037943 | 0.88 | CFTR (0.49) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20162765 | 0.88 | CFTR (0.49) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL27208127 | 0.86 | SRC (0.51) | CFTRKDRRETLCKSRC | |
| SCHEMBL30538114 | 0.85 | CFTR (0.46) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30038273 | 0.85 | CFTR (0.46) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20162612 | 0.85 | CFTR (0.46) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20162611 | 0.85 | CFTR (0.46) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20162622 | 0.83 | CFTR (0.45) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20162663 | 0.83 | KDR (0.48) | CFTRKDRRETLCKSRC | |
| SCHEMBL30036834 | 0.83 | KDR (0.48) | CFTRKDRRETLCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | CFTR 1/4885PI4KA 2428/4885PI4K2B 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.